Triple-negative breast cancer: Pattern of recurrence and survival outcomes

Abstract

Introduction: Triple-negative breast cancer (TNBC) is a subtype of breast cancer which is defined as the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 overexpression by immunohistochemistry. As the survival data on TNBC in the Indian population are scant, this study was done to analyze the clinicopathological features and clinical outcomes of TNBC patients. Materials and Methods: Data from medical records of patients with breast cancer between 2009 and 2014 were retrieved, and patients with TNBC were identified and analyzed for demographic and clinicopathological features. Survival analyses were performed using the Kaplan–Meier method for disease-free survival (DFS) and overall survival (OS). Results: A total of 1024 breast cancer patients were registered at our institute during the study period, of which 198 were TNBCs accounting for 19.3% of all breast cancers. Median age at the diagnosis was 50 years (range, 22–78 years). Lymph nodal positivity in TNBC was associated with larger tumor size (P = 0.003) and higher tumor grade (P = 0.01). At a median follow-up of 48 months (range, 12–88), 36 (19.1%) patients had recurrence of the disease, whereas 28 (14%) patients were lost to follow-up. Lung (52.7%) was the most common site of recurrence followed by bone (25%) and brain (11.1%). Three-year DFS and OS were 63.2% and 65.6%, respectively. On univariate analysis, nodal status, size of tumor, and lymphovascular invasion were found to have a significant impact on OS and DFS. On multivariate analysis, only nodal status was significant for DFS and OS (P < 0.001 and P = 0.001, respectively). Conclusions: TNBCs have a rapid clinical course, and early recurrences are common inspite of timely medical intervention which reflects the aggressive tumor biology. This warrants further studies on intensification of chemotherapy and identification and development of targeted therapy aimed at decreasing recurrences and improving survival in this patient population.

Keywords

Recurrences - survival - triple-negative breast cancer

Publication History

Article published online:
08 June 2021

• References

• 1 International Agency for Research on cancer. GLOBOCAN: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: IARC; 2013. Available from: http://globocan.iarc.fr. [Last accessed on 2019 Mar 19].
• 2 Malvia S, Bagadi SA, Dubey US, Saxena S. et al. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 2017; 13: 289-95
• 3 Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: Current and emerging concepts. Am J Clin Pathol 2014; 141: 462-77
• 4 Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74
• 5 Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-23
• 6 Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R. et al. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat 2012; 136: 795-804
• 7 Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: Challenges and treatment strategies. Drugs 2013; 73: 1257-65
• 8 Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW. et al. Triple-negative breast cancers: Unique clinical presentations and outcomes. Ann Surg Oncol 2010; 17: 384-90
• 9 Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. eds. WHO classification of tumors of the breast, 4th edn. Geneva: World Health Organization. 2012.
• 10 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10
• 11 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer Cancer Staging Manual. New York: Springer. 2010, 7th ed.
• 12 Suresh P, Batra U, Doval DC. Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India. J Med Paediatr Oncol 2013; 34: 89-95
• 13 Lakshmaiah KC, Das U, Suresh TM, Lokanatha D, Babu GK, Jacob LA. et al. A study of triple negative breast cancer at a tertiary cancer care center in Southern India. Ann Med Health Sci Res 2014; 4: 933-7
• 14 Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: Clinical and prognostic implications. Eur J Cancer 2009; 45: 27-40
• 15 Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA. et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34
• 16 Wang XX, Jiang YZ, Li JJ, Song GG, Shao ZM. et al. Effect of nodal status on clinical outcomes of triple-negative breast cancer: A population-based study using the SEER 18 database. Oncotarget 2016; 7: 46636-45
• 17 Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA. et al. Response to neo adjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81
• 18 Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F. et al. Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 2009; 27: 220-6
• 19 Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer-prognostic factors and survival. Radiol Oncol 2011; 45: 46-52
• 20 Chandra D, Suresh P, Sinha R, Azam S, Batra U, Talwar V. et al. Eight year survival analysis of patients with triple negative breast cancer in India. Asian Pac J Cancer Prev 2016; 17: 2995-9